Dimethaid announces new pancreatic cancer trial with WF10
Phase II trial to be initiated at University of Heidelberg
26-Aug-2005 -
Pharmaceutical developer Dimethaid Research Inc. announced that it is commencing a Phase II trial of its immune modulator, WF10, as adjuvant treatment for pancreatic cancer. The study will be conducted at the European Pancreas Center of the University of Heidelberg Clinic for Surgery, Germany, by ...
biology
chemokines
chemotherapy
+8